These
Doctors Say:
Dr.
Frank Woodbine, Ph.D.:
“Pure
Collagen stimulates a source of natural energy in the body and those
who are taking it are becoming self-evident testimonies to the power
of this incredible wellness resource. There is no need to
“try-out” this product. It is an important source of nutrition
for all bodies alike and it works.”
Dr. Bill Trusak, D.C. :
“I’ve been a chiropractor for the past 28 years and
currently run a clinic that sees 200 people a day...I’m so
thrilled to expand my practice with a product that safely and
naturally helps people. I know I can recommend pure collagen and
expect tremendous results for my patients.”
Dr. Edward Lafontaine :
“There is nothing on the market like collagen. I have
been looking for a collagen based product for over 20 years. I have
repeatedly asked manufacturers to formulate a product like pure
collagen to no avail...This is the one fundamental nutrient I
recommend to each and every patient.”
Ron Darling, Health Practitioner:
“I have had the good fortune of monitoring over 300
patients over a one year period on the use of the product...They
included people with high blood pressure, arthritis and many more
conditions. Over that one year my patients averaged 85% of positive
results...Pure collagen is very reliable and safe.”
University
of Tennessee, Memphis, USA.
OBJECTIVE:
Joint inflammation in juvenile rheumatoid arthritis (JRA) is
sometimes associated with an autoimmune response to type II collagen
(CII), a cartilage-specific protein. To test the hypothesis that
down-regulation of autoimmunity to CII can be accomplished in JRA by
oral administration of CII, an open-label study of CII was performed
in 9 patients with JRA....RESULTS:
Eight patient trials met the criteria for clinical improvement
outlined by Giannini and coworkers in 1997. None of the patients had
any side effects from the treatment. In 6 of the
8 patients who improved, interferon-gamma production decreased after
oral CII therapy, correlating with clinical improvement, while 6
patients had increases in levels of transforming growth factor
beta3. CONCLUSION: These results are encouraging.
Beth
Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
OBJECTIVE:
Oral
administration of cartilage-derived type II collagen (CII) has been
shown to ameliorate arthritis
in animal models of
joint inflammation, and preliminary studies have suggested that this
novel therapy is clinically beneficial and safe in patients with
rheumatoid arthritis (RA). The present study was undertaken to test
the safety and efficacy of 4 different dosages of orally
administered CII in patients with RA....No treatment-related adverse
events were detected. The efficacy seen with the lowest dosage is
consistent with the findings of animal studies and with known
mechanisms of oral tolerance in which lower doses of orally
administered autoantigens preferentially induce disease-suppressing
regulatory cells. CONCLUSION: Positive effects were observed with CII at
the lowest dosage tested,
and the presence of
serum antibodies to CII at baseline may predict response to therapy.
No side effects were associated with this novel therapeutic agent.
Rheumatism
Research Center, Catholic Research Institute of Medical Science, The
Catholic University of Korea, Seoul, Korea.
Induction
of oral tolerance has long been considered a promising approach to
the treatment of chronic autoimmune diseases, including rheumatoid
arthritis (RA). Oral
administration of type II collagen (CII) has been proven to improve
signs and symptoms in RA patients without
troublesome toxicity. To investigate the mechanism of immune
suppression mediated by orally administered antigen, we examined
changes in serum IgG subtypes and T-cell proliferative responses to
CII, and generation of IL-10-producing CD4+CD25+ T-cell subsets in
an animal model of collagen-induced arthritis (CIA).....
These
data suggest that when these IL-10-producing CD4+CD25+ T cells
encounter CII (Collagen type II) antigen in affected joints they
become activated to exert an anti-inflammatory effect.
Department of
Rheumatology, University Hospital Jean Minjoz, Bd A. Fleming,
F-25030 Besancon Cedex, France.
Oral tolerance (OT) consists of the oral
administration of antigens (Ag) that could alter the response of the
immune system...In Rheumatoid Arthritis, 4 trials of oral type II
collagen (CII) in RA have been published. Taken together, these
studies suggested that oral
CII in RA gave a trend toward clinical improvement...
Institute of Clinical
Pharmacology, Anhui Medical University, Hefei, China.
The objective of this study was to investigate the
effect of the oral administration of type II collagen (CII) on
pro-inflammatory mediator production by synoviocytes in rats with
adjuvant arthritis (AA). Sprague-Dawley rats were fed with bovine
CII either before immunization with Complete Freund's adjuvant (CFA)
or after initiation of arthritis....We
conclude that oral administration of CII (type II collagen) had
prophylactic and therapeutic effects on AA and
over-production of IL-1, TNF, NO and MDA by synoviocytes was
suppressed. Bystander active suppression may be the main mechanism
of oral CII in the suppression of synoviocyte function.
Guy's Kings, Hospital
School of Medicine, King's College, London, UK.
OBJECTIVE: Previous randomized controlled trials for
treatment of rheumatoid arthritis (RA) with acid-soluble chicken and
bovine type II collagen (CII) have produced conflicting results.
This randomized, double-blind, controlled trial examined the
therapeutic effect of bovine CII tablets in RA....There were no side
effects associated with CII treatment. CONCLUSION:
Treatment with 0.5 mg/day of bovine CII is
well tolerated and produces small, but significant, disease
improvement in Rheumatoid Arthritis....The
difference between our results and those of other trials may relate
to the dose, species, and formulation of the CII.
CEPROCOR (Centro de
Excelencia en Productos y Procesos de Cordoba), Argentina.
We evaluated the efficacy and safety of orally
administered bovine tracheal type II collagen (CGII) in the
treatment of rheumatoid arthritis (RA). Twenty RA patients received
0.5 mg/day of CGII for 12 weeks. Eighteen of them had improvements
in the clinical parameters studied (swollen and tender joint counts,
15-m walking time, duration of morning stiffness, and physician's
global assessment of disease activity)....Although a placebo effect
cannot be discounted,
the
oral administration of bovine tracheal CGII induced clinical
benefits in 90% of the patients, without the side effects usually
associated with treatment. This is the first
study showing that feeding CGII can induce reductions in RF and TNF-alpha.
Department of
Microbiology, Saga Medical School, Japan.
Oral
administration of type II collagen (CII) has been shown to suppress
collagen-induced arthritis (CIA)
in experimental animals...Thus, the neutralization of IL-4 by an
anti-IL-4 Ab appears to be effective in blocking suppression of CIA
by oral administration of CII, suggesting that IL-4 may be
critically involved in its suppression.
Department of
Orthopedic Surgery, Kansai Medical University.
The correlation between the efficacy of type II
collagen (C II) treatment of the rheumatoid arthritis (RA) and the
existence of HLA-DRB 1 * 0405 allele was investigated in two groups
of patients....We concluded that
oral C II could have a therapeutic efficacy
in RA patients with HLA-DRB 1 * 0405 allele.
Department of
Microbiology, Saga Medical School, Japan.
The present study was designed to investigate the
efficacy of oral administration of type II collagen (CII) on
non-specifically induced chronic arthritis in rats, induced by
intra-articular injection of a mineral oil, squalene. When CII was
fed before injection of squalene, no chronic arthritis developed.
Feeding CII after the induction of arthritis was also effective in
suppressing the progression of chronic joint inflammation. In rats
fed and primed with CII, there was a decrease in proliferative
responses to CII. Arthritis induced by the mineral oil was markedly
suppressed by the spleen cells from animals fed CII. These
results indicate that non-specifically induced arthritis may be
downregulated by the oral administration of CII
Brigham and Women's
Hospital, Boston, MA 02115, USA.
OBJECTIVE. To assess the effect of orally
administered type II collagen (CII) in antigen-induced arthritis (AIA)...RESULTS.
Joint swelling was significantly reduced at a dose of 3 micrograms
and 30 micrograms of CII...CONCLUSION.
Oral
CII can suppress arthritis in an animal model in
which immunity to collagen does not play a role. The effect is dose
dependent and occurs at lower doses of CII. These results
demonstrate the biologic relevance of bystander suppression
associated with oral tolerance, and the potential use of this
approach to treat human inflammatory joint disease.
Department of
Medicine, Beth Israel Hospital, Boston, MA.
Rheumatoid arthritis is an inflammatory synovial disease thought to
involve T cells reacting to an antigen within the joint. Type II
collagen is the major protein in articular cartilage and is a
potential autoantigen in this disease....Four patients in the
collagen group had
complete remission of the disease. No side effects were evident.
These data demonstrate clinical efficacy of an oral tolerization
approach for rheumatoid arthritis.
Infection &
Immunity Group, King's College London, U.K.
The
oral administration of CII by gavage to WA/KIR rats before a
conventional arthritogenic challenge with bovine CII in FIA reduced
the incidence (by 23%) and delayed the onset of collagen-induced
arthritis in about 50% of the animals...These
studies show that the oral administration of CII alters the
subsequent immune response to the arthritogenic challenge and
indicate that this oral tolerance of CII is due, not to clonal
deletion or anergy, but rather to an antigen-driven active
suppression mechanism...
